BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Way to Monetary Health: Individual budget Change - 2Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 3Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- 4Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods
- 5The Best Computer games Ever
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Vote in favor of Your #1 4\u00d74 SUVs
- Fundamental Venture The board Apparatuses for Remote Groups
- How does Spotify Wrapped calculate your listening age? What your number says about you.
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
